🔍 They will address manufacturability issues and leverage machine learning to resolve productivity challenges in biotherapeutic production.
🏭 This partnership aims to create real-world solutions for industry challenges, ensuring alignment with cutting-edge biopharmaceutical practices. It’s a significant step forward for Irish biopharma!
Introduction:
The article discusses a strategic partnership between Ireland’s Research Centre for Pharmaceuticals (SSPC) and the National Institute for Bioprocessing Research and Training (NIBRT). This collaboration aims to address significant hurdles in the biopharmaceutical sector, particularly focusing on research and development (R&D) and manufacturing processes.
- The partnership seeks to improve the manufacturability of drug candidates emerging from research laboratories.
- An emphasis is placed on enhancing R&D processes to boost manufacturing efficiencies and product quality.
- SSPC and NIBRT will address bottlenecks in biological production through hybrid mechanistic-machine learning models.
- The collaboration aims to develop technologies that tackle real-world manufacturing challenges in the biopharmaceutical industry.
- Past collaborations have laid a foundation for this partnership, engaging major industry players in addressing common production issues.
Conclusion:
The SSPC and NIBRT partnership represents a significant effort to improve biopharmaceutical development and manufacturing processes. By leveraging advanced research methodologies and collaborative knowledge, they aim to overcome existing challenges in the sector, ensuring that the solutions developed are applicable to real-world manufacturing environments. This partnership signals potential advancements in the biopharmaceutical industry, particularly in the fields of cell and gene therapies.
